What is the revenue and EPS growth rate for AirSculpt year over year?

What were the key takeaways from AirSculpt's earnings call?

What factors drove the changes in AirSculpt's revenue and profit?

What is the market's earnings forecast for AirSculpt next quarter?

What were the key takeaways from AirSculpt’s earnings call?

Did AirSculpt beat or miss consensus estimates last quarter?

What guidance did AirSculpt's management provide for the next earnings period?

What does AirSculpt do and what are its main business segments?

- **Revenue decline**: Q3 $35M (-17.8% YoY), with EBITDA $3M (8.7% margin).

**CEO Summary Section**
- Q3 revenue declined 17.8% YoY to $35M, with same-store sales down 22%.
- Focused on GLP-1 opportunity, expanding skin tightening services and introducing skin excision procedures.
- Repaid $18M debt YTD, with 2025 revenue guidance revised to $153M from prior $160-170M range.

**CFO Financial Commentary**
- Q3 GAAP revenue $35M (-17.8% YoY), with cases down 15.2% to 2,780.
- EBITDA $3M (8.7% margin), vs. $4.7M prior.
- Skin tightening pilot shows higher conversion rates among GLP-1 users.
- Repaid $18M debt, with 2025 EBITDA guidance $16M (vs. prior $16-18M range).

**Q&A Highlights**
- Surgeon interest in skin excision pilots is strong, with 63% GLP-1 users seeking aesthetic procedures.
- Marketing shifts to target GLP-1 patients, with 38% annual growth in GLP-1 prescriptions (2022-2024).

AirSculpt Technologies, Inc. (AIRS) Q3 2025 Earnings Call Transcript

- **Revenue Decline**: Q2 revenue down 13.7% YoY to $44M, with same-store sales down 22%. Narrowed YoY decline by 4 percentage points vs. Q1.
- **Cost Efficiency**: SG&A down $11.6M YoY; CAC improved 13% YoY to $2,905/case.
- **Strategic Momentum**: Record lead growth, 50% financing adoption, and skin tightening pilot expansion planned.
- **Financial Strength**: Debt reduced to $58.8M (2.87x leverage); reiterating $160-170M revenue and $16-18M EBITDA guidance.

**【CEO Summary Section】**
- **Revenue Performance**: Q2 2025 revenue of $44 million (-13.7% YoY), with same-store revenue down 22% YoY. Narrowed YoY decline by 4 percentage points vs. Q1. Average revenue per case remained stable at $12,000-$13,000.
- **Strategic Progress**: 
  - **Marketing**: Lead growth at record highs, CAC down 13% YoY to $2,905/case.
  - **Sales**: Virtual appointments boosted consultations; 50% of patients used financing options.
  - **New Services**: Skin tightening pilot launched in 3 centers, targeting post-GLP-1 patients.
  - **Technology**: Salesforce re-engagement drove higher consultation rates.
- **Financial Health**: Completed $16M debt repayment, reducing leverage to 2.87x. Reiterated 2025 guidance: $160-170M revenue, $16-18M EBITDA.

**【CFO Financial Commentary】**
- **Revenue & EBITDA**: Q2 GAAP revenue $44M (-13.7% YoY), adjusted EBITDA $5.8M (13.3% margin). Cost of service 39.1% of revenue (up 220bps YoY due to fixed costs).
- **Cost Management**: SG&A down $11.6M YoY, driven by reduced marketing and restructuring costs. Sequential EBITDA improvement of $2M.
- **Balance Sheet**: Cash $8.2M, debt $58.8M. Compliance with credit covenant; no new de novo centers planned in 2025.

**【Q&A Key Highlights】**
- **Consumer Sentiment**: Record leads and consultations, but cautious spending. 50% of patients using financing vs. 44% in Q1.
- **Skin Tightening Pilot**: No standalone revenue in guidance; early learnings from 3-center pilot.
- **2024 Centers**: Performing in line with expectations; Q3/Q4 same-store decline to moderate.
- **London Facility**: Cash flow negative but outperformed chain in Q2.
- **Expansion Strategy**: Prioritize same-store growth before considering new centers.

AirSculpt Technologies, Inc. (AIRS) Q2 2025 Earnings Call Transcript

- **Revenue decline**: Q1 2025 revenue down 17.3% YoY to $39.4 million, driven by 17.9% case volume decline.
- **Cost control success**: EBITDA improved $1.9 million vs. Q4, with $3 million annualized savings from workforce reductions.
- **Growth catalysts**: Skin tightening pilot launched in Q2, expanded financing options rolling out by end of Q2.
- **FY25 guidance**: $160-170 million revenue, $16-18 million EBITDA. Targeting same-store sales growth by year-end.
- **Risks**: 44% financing usage reflects macro pressure; elongated booking timelines (60+ days) persist.

**【CEO Summary Section】**
- Q1 2025 revenue: $39.4 million (-17.3% YoY), driven by 17.9% decline in cases. Same-store revenue down 24% YoY, but improving sequentially from Feb to April.
- Adjusted EBITDA: $3.8 million (9.5% margin) vs. $7.3 million (15.4% margin) in Q1 2024. Cost discipline delivered $1.9 million EBITDA improvement vs. Q4 2024.
- Key initiatives:
  - Reallocated marketing spend to SEO/social media, leading to significant lead growth without increased ad spend.
  - Launched skin tightening pilot in Q2, targeting new revenue stream.
  - Expanded financing options to reduce payment barriers, rolling out by end of Q2.
  - Hires of Chief Digital Officer and Chief Sales Officer driving process improvements.
- FY25 guidance: Revenue $160-170 million, EBITDA $16-18 million. Expect same-store sales growth by year-end.

**【CFO Financial Commentary】**
- Cost of service: $15.9 million (40.5% of revenue) vs. $14.8 million (37.9% in Q1 2024), due to fixed costs.
- SG&A: $24.3 million (+$6 million YoY) driven by equity comp. Sequentially down $1.6 million.
- CAC: $3,130/case vs. $2,990 YoY, higher due to lower case volume despite reduced ad spend.
- Cash: $5.6 million. Debt: $74.7 million (3.76x leverage). Cash flow: $0.9 million vs. $3.4 million YoY.
- FY25 outlook assumes no new centers, focuses on existing center growth.

**【Q&A Highlights】**
- **Cost savings**: $3 million annualized from workforce reductions, sustainable through 2025.
- **Growth assumptions**: Low end of guidance assumes continued macro weakness; high end assumes marketing/sales initiatives deliver incremental growth.
- **Skin tightening**: No contribution in 2025, potential upside if pilot succeeds.
- **Consumer trends**: 44% of patients used financing (vs. 50% in Q4), elongated booking timelines (60+ days) due to macro uncertainty.
- **Financing rollout**: Expanded options launching Q2, expected to improve conversion rates.

AirSculpt (AIRS)-2 May 25-2025 Q1 Earnings call transcript

- **Revenue decline**: Q4 2024 revenue down 17.7% YoY, FY 2024 EBITDA margin halved to 11.5%.
- **Strategic reset**: Paused de novo openings; $3M annual cost savings implemented.
- **Growth drivers**: New marketing channels (online video), standalone skin tightening pilot, and payment flexibility to improve lead conversion.
- **Financial focus**: Sequential sales improvement expected in 2025, with Q1 same-store performance mirroring Q4 2024.

**【CEO Opening Remarks】**
- Q4 2024 revenue: $39.2M (-17.7% YoY), same-store revenue down 22.6% YoY due to reduced marketing spend and macro pressures.
- FY 2024 revenue: $180.4M (-7.9% YoY), Adjusted EBITDA: $20.7M (11.5% margin vs. 22.1% in 2023).
- Strategic priorities: 
  1. Marketing optimization (e.g., online video, social media) to increase leads.
  2. Sales process enhancement with new Chief Sales Officer.
  3. New services (e.g., standalone skin tightening pilot in Q2 2025).
  4. Customer experience improvements.
  5. Technology investments (e.g., payment flexibility, salesforce platform).
- Paused de novo openings to focus on same-store growth; 5 new centers opened in 2024 with mixed performance.
- Q1 2025 same-store sales expected to mirror Q4 2024 decline, with sequential improvement as marketing efforts gain traction.

**【CFO Financial Review】**
- Q4 2024 Adjusted EBITDA: $1.9M (4.7% margin vs. 21.2% YoY), driven by revenue decline and cost rigidity.
- FY 2024 cash flow from operations: $11.4M vs. $24M in 2023; $9M invested in new centers.
- Leverage ratio: 3.0x at year-end, compliant with credit covenant amendments.
- Customer acquisition cost (CAC): $3,250/case (vs. $2,600 YoY), expected to decline with improved conversion.
- Q1 2025 outlook: same-store revenue decline similar to Q4 2024, no new center openings.

**【Q&A Highlights】**
- **Marketing & CAC**: Rebalanced marketing spend toward high ROI channels (e.g., online video), with early lead volume increases in Q1 2025. CAC expected to normalize as conversion rates improve.
- **Cost Savings**: $3M annualized cost out (e.g., corporate headcount reduction), realized in Q1 2025.
- **Skin Tightening Pilot**: Testing standalone service in select centers to capitalize on GLP-1 trend; potential for incremental revenue.
- **Liquidity**: Revolver draw in Q4 2024 to maintain marketing flexibility; focused on de novo openings when same-store growth stabilizes.

Actual	0.11	0.035	-0.01	0.01	-0.13	0.07	0.1	0.13	0.01	0.03	0.09	-0.02	-0.08	-0.02	0.02	-0.04
Forecast	0.1367	0.0475	0.0375	0.0425	0.0575	0.06	0.13	0.15	0.105	0.08	0.13	-0.0028	0.0169	-0.0333	0.0067	-0.02
Surprise	-19.53%	-26.32%	-126.67%	-76.47%	-326.09%	+16.67%	-23.08%	-13.33%	-90.48%	-62.50%	-30.77%	-614.29%	-573.37%	+39.94%	+198.51%	-100.00%

AIRS

AIRS fundamentals

AIRS Q3 2025 Earnings

Earnings Call

You can ask Aime

AIRS

AIRS fundamentals

AIRS Q3 2025 Earnings

Earnings Call

AIRS Earnings Call Summary for Q3/20258:30 AM on Nov 7, 2025

AIRS Earnings Call Summary for Q2/20258:30 AM on Aug 1, 2025

AIRS Earnings Call Summary for Q1/20258:00 AM on May 2, 2025

AIRS Earnings Call Summary for Q4/20248:30 AM on Mar 14, 2025

AIRS Earnings Call Summary for Q3/20248:00 AM on Nov 8, 2024

You can ask Aime